Fig. 2. Kaplan Meier survival analysis showing association of expression of ADAMTS1 with patient outcome. a) Disease-free survival curve in breast cancers patients that received systemic treatment with low or high levels of ADAMTS1 (mean Affymetrix probe set probes 222162_s-at & 222486_s_at, n=751). b) Disease-free survival curve in node negative breast cancers with low or high levels of ADAMTS1 (n=451). c) Distant metastasis-free survival curve breast cancers patients that received systemic treatment with low or high levels of ADAMTS1 (n=324). Distant metastasis free survival curve in lymph node breast cancers patients with low or high levels of ADAMTS1 (n=162). e) Overall survival curve in breast cancers patients that received systemic treatment with low or high levels of ADAMTS1 (n=107). f) Overall survival curve in lymph node positive breast cancers patients with low or high levels of ADAMTS1 (n=77).